Products
-
- BBB DamageCell Death and ApoptosisNeuroinflammationNeuronal Damage and RepairOxidative StressVascular Mechanisms
- 3D BBB Models
- Organ-on-a-Chip BBB ModelsTranswell Models3D BBB Models Culture Substrate
- 3D HydrogelsCollagensAnmial BBB ModelsCell Lines for BBB Modeling
- Immortalized CellsPrimary CellsStem Cells
Recombinant Human NRG1 Protein (Fc Tag) (AC1111)
Cat.#: ACPP-1111
Specifications
Despition Recombinant Human NRG1 Protein (Fc Tag) for ELISA, SDS-PAGE SIZE 50 µg Source Recombinant Protein Length Fragment Expression System HEK293 cells Protein Species Human Sequence NRG1 (Ser20-Arg242) + hFc (Glu99-Ala330) Molecular Weight 50.3 kDa without signal peptide Purity > 95% by SDS-PAGE and Coomassie blue staining. Form Lyophilized Tag C-terminal Human Fc Tag Applications ELISA, SDS-PAGE Storage Lyophilized was stored at -20°C to -80°C, while reconstituted was aliquot and stored at -80°C. Avoid freeze/thaw cycles. Shipping Shipped at 4°C Citation Guidance If you use our product in a scientific publication, please cite it as "Ace Therapeutics Cat.#". Click here to submit your paper's PubMed ID (PMID) to receive rewards. Related Products
Cat.# Name Size Price ACPP-1442 Human TBCB Protein (AC1442) 5 µg inquiry ACPP-1574 Human NDUFS4 Protein (AC1574) 5 µg inquiry ACPP-1355 MERTK Blocking Peptide (AC1355) 250 µg inquiry ACPP-1552 Human CDNF Protein (AC1552) 5 µg inquiry ACPP-1057 Recombinant Human Prion Protein PrP Protein (Fc Tag) (AC1057) 50 µg inquiry ACPP-1466 Human ATG10 Protein (AC1466) 5 µg inquiry ACPP-1601 Rat ACRP30 Protein (AC1601) 2 µg inquiry ACPP-1398 Rat TIMP1 Protein (AC1398) 2 µg inquiry ACPP-1175 Recombinant Mouse Syndecan-1 Protein (Fc Tag) (AC1175) 50 µg inquiry ACPP-1322 TRPM8 Blocking Peptide (AC1322) 250 µg inquiry All of our products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.
Ace Therapeutics is a global leading provider of stroke research services. We are committed to accelerating progress in stroke research and drug development.
0Inquiry Basket